Target Name: MIGA1
NCBI ID: G374986
Review Report on MIGA1 Target / Biomarker Content of Review Report on MIGA1 Target / Biomarker
MIGA1
Other Name(s): Mitoguardin 1 | Mitoguardin 1 (isoform 1) | MIGA1 variant 1 | FLJ35093 | FAM73A | family with sequence similarity 73, member A | DKFZp686M07166 | protein FAM73A | Mitoguardin 1, transcript variant 1 | MIGA1_HUMAN | mitoguardin 1

MIGA1: A Potential Drug Target and Biomarker

Mitoguardin 1 (MIGA1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Mitoguardin family, which includes several similar proteins that have been implicated in various cellular processes, including cell signaling, cell adhesion, and inflammation. MIGA1 has been shown to play a role in several physiological processes, including the regulation of insulin secretion from pancreatic beta cells, the development and progression of cancer, and the regulation of inflammation.

One of the key functions of MIGA1 is its role in insulin secretion. MIGA1 has been shown to regulate the amount of insulin that is released from pancreatic beta cells in response to changes in blood sugar levels. MIGA1 has been shown to play a negative role in the development of insulin resistance, which is a condition in which the body's cells become less responsive to insulin, making it difficult for glucose to enter the cells.

In addition to its role in insulin secretion, MIGA1 has also been shown to be involved in the development and progression of cancer. MIGA1 has been shown to promote the growth and survival of cancer cells, and it has been shown to play a role in the development of pancreatic cancer, one of the most aggressive forms of cancer.

MIGA1 has also been shown to be involved in inflammation. MIGA1 has been shown to contribute to the regulation of inflammation in the body, and it has been shown to play a role in the development of various inflammatory diseases, including cancer and autoimmune diseases.

Given the multiple roles that MIGA1 has been shown to play in various physiological processes, it is a promising target for drug development. MIGA1 has been shown to be a potential drug target in several different organisms, including mammals, and it has been shown to have a high degree of cross-reactivity.

In addition to its potential as a drug target, MIGA1 has also been shown to be a potential biomarker. MIGA1 has been shown to be expressed in a variety of tissues and has been shown to be involved in several physiological processes, including insulin secretion, cancer development, and inflammation. As such, MIGA1 has been suggested as a potential biomarker for a variety of diseases, including cancer, insulin resistance, and pancreatic disease.

In conclusion, MIGA1 is a protein that has been shown to play a role in several physiological processes, including insulin secretion, cancer development, and inflammation. As such, it is a promising target for drug development and a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of MIGA1 in these processes and to develop effective treatments.

Protein Name: Mitoguardin 1

Functions: Regulator of mitochondrial fusion: acts by forming homo- and heterodimers at the mitochondrial outer membrane and facilitating the formation of PLD6/MitoPLD dimers. May act by regulating phospholipid metabolism via PLD6/MitoPLD

The "MIGA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIGA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248